IONS
Ionis Pharmaceuticals, Inc.
Stock
$43.54−0.46 (−1.05%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$496M | −$269M | −$501M | −$308M | −$274M | $31M | $36M | $346M | $603M | $174M | −$112M | $21M | $6.3M | $63M | $1.9M | −$115M | −$64M | −$108M | $212M |
| Capital expenditures | $64M | $51M | $45M | $24M | $16M | $12M | $35M | $31M | $14M | $35M | $7.1M | $7.7M | $7.5M | $1.6M | $1.5M | $10M | $13M | $13M | $14M |
| Free cash flow | −$561M | −$320M | −$546M | −$331M | −$290M | $19M | $772K | $315M | $589M | $139M | −$119M | $13M | −$1.2M | $62M | $397K | −$125M | −$77M | −$122M | $198M |
| Stock-based compensation | $163M | $134M | $130M | $106M | $100M | $121M | $230M | $147M | $131M | $86M | $72M | $59M | $31M | $11M | $8.6M | $9.8M | $12M | $13M | $15M |
| Buybacks | — | — | — | — | $0 | $0 | $91M | $34M | $0 | $0 | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | −64.2% | −33.9% | −77.5% | −42.1% | −49.4% | 2.3% | 0.1% | 28.0% | 98.3% | 27.5% | −34.4% | 4.7% | −0.6% | 42.1% | 0.4% | −126.2% | −70.8% | −100.2% | 185.1% |